Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: Role of pharmacokinetics

Journal of the American College of Cardiology

Volumn 29, Issue 7, 1997, Pages 1607-1614

  Wenzel, René R ^a   Allegranza, Giuseppe ^a   Binggeli, Christian ^a   Shaw, Sidney ^a   Weidmann, Peter ^a   Lüscher, Thomas F ^a   Noll, Georg ^a  

^a U   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NIFEDIPINE;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG RELEASE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; VASCULAR RESISTANCE; VASOCONSTRICTION;

BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; HEART RATE; HUMANS; NIFEDIPINE; NOREPINEPHRINE; PERONEAL NERVE; SKIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 0030987917     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00095-8     Document Type: Article

References (39)

1. Lund-Johansen P. Central haemodynamics in essential hypertension at rest and during exercise a 20-year follow-up study . J Hypertens. 7:(Suppl):1989;S52-S55.
2. Maseri A, Pesola A, Marzilli M, et al. Coronary vasospasm in angina pectoris. Lancet. 1:1977;713-717.
3. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans effects of age, atherosclerosis, hypercholesterolemia, and hypertension . J Clin Invest. 92:1993;652-662.
4. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet. 336:1990;1144-1147.
5. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
6. Nayler WG, Szeto J. Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res. 6:1972;120-128.
7. Dohi Y, Criscione L, Pfeiffer K, Lüscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension studies in perfused mesenteric resistance arteries . J Cardiovasc Pharmacol. 24:1994;372-379.
8. Yang Z, Noll G, Lüscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 88:1993;832-836.
9. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 68:1981;1366-1369.
10. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990;335:1109-13.
11. HINT: early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both: report of The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 1986;56:400-13.
12. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina an overview . BMJ. 299:1989;1187-1192.
13. The effect of diltiazem on mortality and reinfarction after myocardial infarction the Multicenter Diltiazem Postinfarction Trial Research Group . N Engl J Med. 319:1988;385-392.
14. Secondary prevention with verapamil after myocardial infarction: the Danish Study Group on Verapamil in Myocardial Infarction. Am J Cardiol 1990;66:33I-40I.
15. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
16. Furberg C, Psaty BM, Meyer JV. Nifedipine dose-related increase in mortality in patients with coronary heart disease . Circulation. 92:1995;1326-1331.
17. McCance AJ, Forfar JC. Cardiac and whole body [3H]noradrenaline kinetics in ischaemic heart disease contrast between unstable anginal syndromes and pacing induced ischaemia . Br Heart J. 61:1989;238-247.
18. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality CONSENSUS Trial Study Group . Circulation. 82:1990;1730-1736.
19. Leimbach WJ, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 73:1986;913-919.
20. Iskandrian AS, Hakki AH, Laddu A. Effects of esmolol on cardiac function evaluation by noninvasive techniques . Am J Cardiol. 56:1985;27F-32F.
21. Porter TR, Eckberg DL, Fritsch JM, et al. Autonomic pathophysiology in heart failure patients sympathetic-cholinergic interrelations . J Clin Invest. 85:1990;1362-1371.
22. Noll G, Wenzel RR, Schneider M, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation. 93:1996;866-869.
23. Delius W, Hagbarth KE, Hongell A, Wallin BG. General characteristics of sympathetic activity in human muscle nerves. Acta Physiol Scand. 84:1972;65-81.
24. Noll G, Elam M, Kunimoto M, Karlsson T, Wallin BG. Skin sympathetic nerve activity and effector function during sleep in humans. Acta Physiol Scand. 151:1994;319-329.
25. Schmid BJ. Determination of nifedipine and its principal metabolites in plasma and urine by automated electron-capture capillary chromatography. J Chromatogr. 425:1988;107-109.
26. Reid JL. Central and peripheral autonomic control mechanisms. Bannister SR. Autonomic Failure. 1989;44-55 Oxford University Press, New York.
27. Hagbarth KE, Hallin RG, Hongell A, Torebjork HE, Wallin BG. General characteristics of sympathetic activity in human skin nerves. Acta Physiol Scand. 84:1972;164-176.
28. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension. 24:1994;287-296.
29. Ferguson DW, Hayes DW. Nifedipine potentiates cardiopulmonary baroreflex control of sympathetic nerve activity in healthy humans direct evidence from microneurographic studies . Circulation. 80:1989;285-298.
30. Kiowski W, Erne P, Bertel O, Bolli P, Bühler F. Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol. 7:1986;344-348.
31. Arzilli F, Gandolfi E, Del Prato C, et al. Antihypertensive effect of once daily sustained release isradipine a placebo controlled cross-over study . Eur J Clin Pharmacol. 44:1993;23-25.
32. Victor RG, Leimbach WJ, Seals DR, Wallin BG, Mark AL. Effects of the cold pressor test on muscle sympathetic nerve activity in humans. Hypertension. 9:1987;429-436.
33. Krakoff LR. Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension results of the MATH Trial . J Cardiovasc Pharmacol. 21:1993;S14-S17.
34. Siu SC, Jacoby RM, Phillips RT, Nesto RW. Comparative efficacy of nifedipine gastrointestinal therapeutic system versus diltiazem when added to beta blockers in stable angina pectoris. Am J Cardiol. 71:1993;887-892.
35. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta inhibition of endothelium-derived nitric oxide . J Clin Invest. 85:1990;587-590.
36. Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol Sci. 10:1989;374-378.
37. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 276:1996;1328-1331.
38. Noll G, Wenzel RR, De Marchi S, Lüscher TF. Differential modulation of the sympathetic nervous system by captopril and nitroglycerin. Circulation. In press.
39. Kerckhoff W, Drewes LR. Transfer of the calcium-antagonists nifedipine and nimodipine across the blood-brain barrier and their regional distribution in vivo. J Cerebr Blood Metab. 5:(Suppl 1):1985;459-460.